37 C
Vientiane
Friday, April 25, 2025
spot_img
Home Blog Page 1792

Doctor Anywhere acquires Singapore-listed Asian Healthcare Specialists, secures additional US$38.8 million funding

Acquisition of integrated healthcare provider Asian Healthcare Specialists marks expansion of strategic capabilities, builds holistic healthcare offering to serve Southeast Asia

SINGAPORE – Media OutReach – 21 December 2022 – Doctor Anywhere (DA), a regional tech-led healthcare company headquartered in Singapore, announced that it has acquired Catalist-listed Asian Healthcare Specialists (SGX:1J3), an integrated healthcare provider in Singapore.

L-R: Mr Travis Seet, CFO and Dr Chin Pak Lin, Chief Executive Officer of Asian Healthcare Specialists; Mr Lim Wai Mun, Founder & CEO and Mr Edwin Basuki, CFO of Doctor Anywhere
L-R: Mr Travis Seet, CFO and Dr Chin Pak Lin, Chief Executive Officer of Asian Healthcare Specialists; Mr Lim Wai Mun, Founder & CEO and Mr Edwin Basuki, CFO of Doctor Anywhere

Asian Healthcare Specialists is a group of 14 medical specialists, with a patient-first approach and vision to make specialised care accessible to all. Its 12 specialist clinics across multidisciplinary specialities comprise orthopaedics, ophthalmology, dermatology, urology, gastroenterology, otorhinolaryngology, anaesthesia, family medicine and rehabilitation – all areas that complement DA’s regional healthcare services and offer consumers greater access to complex treatments.

The acquisition is a strategic step to further DA’s long-term growth ambitions, enabling it to deliver more holistic healthcare and meet the rising demand for complex, specialised treatment across Southeast Asia.

“Our goal at Doctor Anywhere is to build a digital healthcare ecosystem to enable better patient outcomes and help shape the future of healthcare in Southeast Asia. With consumers across the region seeking higher quality and more personalised care, the acquisition of Asian Healthcare Specialists strengthens our capabilities beyond our successful primary care services, enabling us to deliver more integrated, holistic care and greater value for our users,” said Lim Wai Mun, Founder & CEO, Doctor Anywhere.

“We continue to be on the lookout for synergistic opportunities and targeted acquisitions of critical healthcare assets across the region, which will enable us to further the work we have begun on building a regional healthcare ecosystem that leverages technology and innovation. A more diversified and holistic range of integrated healthcare service offerings will enable Doctor Anywhere to deliver greater value and impact to elevate the region’s healthcare outcomes,” added Wai Mun.

Chief Executive Officer of Asian Healthcare Specialists Limited, Dr Chin Pak Lin commented, “Coupled with shifting demographics, technological innovations, and the diverse nature of healthcare infrastructure across Southeast Asia, we’re currently sitting at the nexus of potential transformation. We are excited to join Southeast Asia’s largest omni-channel healthcare provider and bring our well-established specialist care expertise to the group. We look forward to working together to bridge the gap between primary and specialised care to provide seamless, holistic care that transcends boundaries and statuses.”

Additional funding bolstered by latest Series C1 financing round

Doctor Anywhere also announced a US$38.8 million Series C1 financing round, an up round led by Novo Holdings, a leading international life science investor. Other existing shareholders also participated in the round, including Asia Partners, Kamet Capital, Square Peg, IHH Healthcare, EDBI and OSK-SBI Venture Partners.

The funding will be used to accelerate growth and to partly fund the acquisition of Asian Healthcare Specialists. It comes just over a year after the company raised a US$65.7 million Series C in August 2021 in one of the largest private funding rounds ever raised by a healthtech company in Southeast Asia. This brings the total capital raised by Doctor Anywhere to nearly US$140 million.

“Doctor Anywhere has shown an exceptional track record since its inception, and today it has firmly established itself as a regional leader in healthcare, successfully integrating seamless online and offline approaches to bring easily accessible and affordable healthcare to millions across Southeast Asia,” said Dr Amit Kakar, Senior Partner, Head of Novo Holdings Equity Asia.

“We are confident in DA’s growth as it builds a regional ecosystem to bring delivery of patient care to the next level, in line with its vision to become the leading tech-enabled omnichannel healthcare provider in Southeast Asia,” he added.

Carol Wang, Senior Associate at Novo Holdings Equity Asia, added: “We are particularly excited to lead this up round to fund the accretive acquisition of Asian Healthcare Specialists. With the addition of the synergistic specialist clinics, we believe that DA would further enhance patient journeys seamlessly through its fully integrated online and offline offerings and would further differentiate itself as a leading omnichannel healthcare provider in Southeast Asia, enabled by its innovative technologies. We look forward to continuing to back DA’s long-term vision, which is perfectly aligned with our deep expertise and commitment in tech-enabled healthcare services.”

Hashtag: #DoctorAnywhere

The issuer is solely responsible for the content of this announcement.

About Novo Holdings

Novo Holdings is a holding and investment company that is responsible for managing the operating and financial assets of the Novo Nordisk Foundation, one of the world’s largest enterprise foundations. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novozymes (the Novo Group companies) and manages an investment portfolio, with a long-term return perspective. The investment portfolio comprises two teams: Life Science Investments and Novo Capital Investors. The Life Science Investments team invests in companies at all stages of development and includes Novo Seeds, Novo Ventures, Novo Growth and Principal Investments. The Novo Capital Investors team manages a broad portfolio of equities, bonds, real estate and infrastructure assets, as well as private equity investments.

Novo Holdings operates out of offices in Copenhagen, London, Boston, San Francisco, Singapore and Shanghai. As of year-end 2021, Novo Holdings had total assets of USD 106 billion. Further information: .

About Doctor Anywhere

Doctor Anywhere is a regional tech-enabled, omnichannel healthcare company, on a mission to make healthcare simple, accessible, and efficient for everyone. Doctor Anywhere’s digital platform bridges gaps in the healthcare ecosystem through technology and innovation, enabling users to manage their health easily and effectively through the DA mobile app. Headquartered in Singapore and with a presence in six countries across the region, Doctor Anywhere now serves more than 2.5 million (and growing) users across Southeast Asia. For more information, visit:

About Asian Healthcare Specialists

Asian Healthcare Specialists Limited is incorporated in Singapore and listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (the “SGX-ST”), and the Company’s sponsor is RHT Capital Pte. Ltd. The Group is a multidisciplinary medical services group providing an extended range of medical services such as anaesthesia, dermatology, family medicine, gastroenterology, ophthalmology, orthopaedics, otorhinolaryngology, rehabilitation and urology. The Group currently has 14 medical specialists in different divisions, one family physician and one physiotherapist, located at 12 clinics in Singapore.

Hong Kong Life Launches “Family Guardian Refundable Hospital Income Protection Plan” with Market-first Family Daily Hospital Income Benefit Providing 100% Premium Refund and additional No Claim Bonus upon Maturity

HONG KONG SAR – Media OutReach – 21 December 2022 – Unpredictable accidents and illnesses may incur high medical expenses and loss of income during hospitalization. Hong Kong Life Insurance Limited (“Hong Kong Life”) launches the Family Guardian Refundable Hospital Income Protection Plan (“The Plan”) with Daily Hospital Income and Intensive Care Benefit to alleviate the financial burden of the customers in case of hospitalization. The Plan’s first-in-market# feature offers Family Daily Hospital Income Benefit, under which both the Life Insured and the Covered Family Member can enjoy the protection of hospitalization in a single policy. Customers are entitled to a premium refund equivalent to 100% of the Total Premiums Paid upon maturity. An extra 3% of Total Premiums Paid will be paid as No Claim Bonus if no claim has been made during the Benefit Term.

Mr. Jonathan Ko, the Chief Marketing Officer of Hong Kong Life, said, “We understand that most customers are willing to strengthen their life and healthcare protection for both individual and family after the pandemic. Compared with most of the hospital income insurance plans in the market which mainly provide personal protection, Family Guardian Refundable Hospital Income Protection Plan is specially designed with family protection feature. The first-in-market# Family Daily Hospital Income Benefit showcases the customer-centric philosophy of Hong Kong Life. Customer and his designated family member are covered with daily hospital income protection by one premium budget, providing peace-of-mind for unexpected hospitalization expenses in case of emergencies.”

Limited Time Offer of First Year Premium Discount

From now until 30 June 2023, customers may enjoy 10% first year premium discount upon successful application of Family Guardian Refundable Hospital Income Protection Plan.

Product Features of “Family Guardian Refundable Hospital Income Protection Plan”:

  • Daily Hospital Income for Flexible Use

If the Life Insured is confined in hospital due to Injury or Sickness while the Plan is in force and prior to the Maturity Date, the Daily Hospital Income Benefit1 will be paid for each day of Hospital Confinement2, with a maximum number of days of Hospital Confinement2 up to 1,000 days per Disability.

  • Intensive Care Benefit

If the Life Insured is confined in Intensive Care Unit due to Injury or Sickness while the Plan is in force and prior to the Maturity Date, in addition to the Daily Hospital Income Benefit, the Intensive Care Benefit1 will be paid for each day of Hospital Confinement2 only when the Daily Hospital Income Benefit is also payable for the same Disability, with a maximum number of days of Hospital Confinement2 up to 90 days per Disability.

  • 3 Classes of Daily Hospital Income

The Plan provides 3 classes of Daily Hospital Income for selection, i.e., HKD600, HKD1,000 and HKD1,500 in order to meet your need.

  • 10-Year Protection with Premium Refund

The Plan offers 10 years of protection to the Life Insured. Also, the Plan provides premium refund. Maturity Benefit which is equal to 100% of Total Premiums Paid will be paid if the Life Insured is then alive on the Maturity Date. Provided that no death claim is made in the benefit term of the Plan, if you surrender the Policy prior to the Maturity Date, the Surrender Benefit will be paid to the Policyowner. The Surrender Benefit equals to a percentage of Total Premiums Paid for the Plan by referring to the Schedule of Surrender Benefit in “Benefit Coverage” at the time of surrender.

  • No Claim Bonus

If the Life Insured is then alive on the Maturity Date, provided that no surrender and no claim has been made under Daily Hospital Income Benefit1 (or Family Daily Hospital Income Benefit1,3, where applicable), Intensive Care Benefit1 or Surrender Benefit, an extra 3% of Total Premiums Paid will be paid as No Claim Bonus.

  • Life Protection for Peace of Mind

Apart from Daily Hospital Income Benefit, the Plan also offers life protection. If the Life Insured dies while the Plan is in force and prior to the Maturity Date, the Guaranteed Death Benefit which is equal to 105% of Total Premiums Paid will be paid to the Beneficiary.

  • Additional Protection and Service to Meet the Needs of You and Your Family

First-in-Market# Family Daily Hospital Income Benefit1,3

The Plan specially offers Family Daily Hospital Income Benefit1,3 to one of the Policyowner’s spouse or children (except the Life Insured). No medical examination and health questions are required for the Covered Family Member. If the Covered Family Member is confined in hospital due to Injury or Sickness while the Plan is in force and prior to the Maturity Date, the Family Daily Hospital Income Benefit1,3 will be paid to the Policyowner for each day of Hospital Confinement2. Throughout the benefit term of the Plan, the maximum number of days of Hospital Confinement2 for Family Daily Hospital Income Benefit1,3 is 10 days.

Second Medical Opinion from Overseas Expert Service4

If the Life Insured has been diagnosed with the dread disease covered by the service, the service enables the Life Insured to seek second medical opinion from overseas experts4.

  • Fixed Premium for Your Better Planning

The premium will remain unchanged throughout the Premium Payment Term5, allowing you to have a better plan for your future.

  • Simple Application

Application procedure is simple and no medical examination is required.

For more details of the Family Guardian Refundable Hospital Income Protection Plan, please visit https://www.hklife.com.hk/en/products/personal-insurance/medical-dread-disease-plan/family-guardian-refundable-hospital-income-protection-plan/index.html

Terms and Conditions apply. For enquiries, please contact our Customer Service Hotline at 2290 2882 or visit Hong Kong Life website www.hklife.com.hk.

Remarks:

# “First-in-market” is stated by comparing to the same type of hospital income insurance products on the market as of September 2022 when Family Guardian Refundable Hospital Income Protection Plan was first launched.

  1. The Daily Hospital Income Benefit (or Family Daily Hospital Income Benefit, where applicable) or Intensive Care Benefit is only payable once for any one day of Hospital Confinement, regardless of the number of Disability per Hospital Confinement. If more than one Hospital Confinement are caused by the same or related Disability, Hong Kong Life will regard such multiple Hospital Confinements as being caused by the same Disability. In the case where Hospital Confinement occurs in places other than Hong Kong, Macau, Singapore, Malaysia, Thailand, Japan, North America, Europe, Australia and New Zealand, the amount of the benefit payable for each day of Hospital Confinement will be limited to 50% of the amount of Daily Hospital Income Benefit (and Family Daily Hospital Income Benefit, where applicable) and Intensive Care Benefit as shown on the Hospitalization Benefit Schedule, and subject to a maximum of 90 days for any one Disability (applicable for Daily Hospital Income Benefit and Intensive Care Benefit) or a maximum of 10 days for the Plan (applicable for Family Daily Hospital Income Benefit, where applicable). The Daily Hospital Income Benefit (and Family Daily Hospital Income Benefit, where applicable) and Intensive Care Benefit are payable on Medically Necessary Hospital Confinement basis. “Medically Necessary” means in respect of Hospital Confinement, treatment, procedure, supplies or other medical services, such Hospital Confinement, treatment, procedure, supplies or other medical services which are, in the Hong Kong Life’s opinion: (i) required for, appropriate and consistent with the symptoms and findings or diagnosis and treatment of the Disability; (ii) in accordance with generally accepted medical practice and not of an experimental or investigative nature; (iii) not for the convenience of the Policyowner, Life Insured (or the Covered Family Member, where applicable), or Registered Medical Practitioner or any other person; and (iv) not able to be omitted without adversely affecting the medical condition of the Life Insured (or the Covered Family Member, where applicable).
  2. “Hospital Confinement” means the admission and confinement of the Life Insured (or the Covered Family Member, where applicable) as an in-patient in a Hospital upon recommendation of a Registered Medical Practitioner for the treatment of a Disability provided that the Life Insured (or the Covered Family Member, where applicable) must be admitted in the Hospital as an in-patient for a minimum of 6 hours and continuously Stay in the Hospital thereafter prior to the Discharge of the Life Insured (or the Covered Family Member, where applicable), which incurs a charge for daily room and board of Hospital room or Intensive Care Unit. Hospital Confinement must be Medically Necessary.
  3. Family Daily Hospital Income Benefit for Policyowner’s legally married spouse or natural child, except the Life Insured (Covered Family Member) is only available if such spouse or child is accepted and approved by Hong Kong Life. Only one Covered Family Member can be covered under Family Daily Hospital Income Benefit. Spouse shall be (i) under the age of 60 at the time of application for Family Daily Hospital Income Benefit and (ii) under the age of 70 throughout the benefit term of the Plan. Child shall be attained the age of 15 days and is under the age of 18. Family Daily Hospital Income Benefit could be claimed a maximum of 10 days throughout the benefit term of the Plan. In no event shall the aggregate amount of benefit payable under the Family Daily Hospital Income Benefit of the Policy and all other insurance policies covering the Covered Family Member issued by Hong Kong Life from time to time, exceed a maximum aggregate amount of HKD1,500 for each day of Hospital Confinement. For detailed terms and conditions, please refer to relevant form and the policy document issued by Hong Kong Life.
  4. Second Medical Opinion from Overseas Expert Service is provided by third party service provider. Such service is not part of the product features. The availability of the service is not guaranteed. The details of the service will be provided along with the policy document or please refer to the company website of Hong Kong Life. Hong Kong Life reserves the right to cancel or amend the said service at its sole discretion. In addition, Hong Kong Life will not be responsible for any services or opinions provided by the third-party service provider. Hong Kong Life reserves the right of final decision in case of any dispute.
  5. The Policy will be terminated if the Policyowner cannot settle the premium payment before the end of the Grace Period during the Premium Payment Term, subject to the Non-forfeiture Option and other relevant provisions of the Policy. For detailed terms and conditions, please refer to the policy document issued by Hong Kong Life. If the Policy is terminated before the Maturity, the Guaranteed Surrender Value received by the Policyowner may be less than the Total Premiums Paid.

Hashtag: #HongKongLife

The issuer is solely responsible for the content of this announcement.

About Hong Kong Life

Established in 2001, Hong Kong Life Insurance Limited (“Hong Kong Life”) was founded by five local financial institutions including Asia Insurance Company Limited, Chong Hing Bank Limited, CMB Wing Lung Bank Limited, OCBC Wing Hang Bank Limited and Shanghai Commercial Bank Limited, which laid their foundations and have been serving people in Hong Kong for more than 50 years in average. Through our extensive network of around 140 distribution points comprising Chong Hing Bank, CMB Wing Lung Bank, OCBC Wing Hang and Shanghai Commercial Bank, we provide a comprehensive range of insurance services

Vietnam Starts its Biggest Lao Project Construction in Sekong

Stone laying ceremony for the start of the Bauxite-Alumina Mining Industrial Complex project (photo: https://english.vov.vn/)

Construction of the Bauxite-Alumina Mining Industrial Complex began in Sekong’s Dakcheung district on 19 December.

Prudential Laos Signs MOU to Build Life Insurance Awareness in the Country

Prudential Life Assurance (Lao) Company Limited (“Prudential Laos”)  signed a Memorandum of Understanding (MoU) with the Department of State Own Enterprise Reform and Insurance (DSRI, Ministry of Finance of Laos) on a Regulatory Sandbox program to build life insurance awareness in Laos in December. 

Code-Create Introduces AiDA by AiDLab, The World’s First Fashion AI Platform For Limitless Original Designs Based On Designer’s Creative Inspirations

Featuring key component Mixi, a style search engine which identifies 2,300 Pantone colours and activates automatic tagging with over 230 fashion attributes

HONG KONG SAR – Media OutReach – 21 December 2022 – Code-Create, the spinoff of the Laboratory for Artificial Intelligence in Design (AiDLab), introduced AiDA, the world’s first fashion AI platform for limitless design inspirations at Fashion X AI: 2022-2023 International Salon on December 19, 2022. International brands and designers debuting their first fashion AI collections with AiDA included Besfxxk, INJURY, The World Is Your Oyster, Mountain Yam, Kay Kwok and Fengyi Tan.

Code.jpg

AiDA: Virtual Mastermind For Limitless Fashion Inspirations

Speaking at the event, Code-Create Co-founder and Chief Executive Officer Kim Wong said, “Code-Create’s mission is to revitalize the fashion ecosystem through AI. AiDA is transforming the way how we fashion and retail new designs.”

As she said, AiDA speeds up the fashion design process, saving more than 60% of the time on design inspiration and development. Beginners can learn all the magic and tricks in 5 minutes.

Code-Create Co-founder Professor Calvin Wong who is currently serving as the Centre Director of AiDLab and has invented AiDA with Dr Aemika Zou and the research team, explained, “AiDA is the first-in-market technology that can generate original designs for single fashion items, or a lineup of outfits based on designer’s creative inspirations in 10 seconds. Equipped with a variety of AI technologies, AiDA can recognize a designer’s inspirations through mood boards, colour choices, fabric print selections and sketches to generate limitless design proposals to spark designers’ creativity.”

Mixi: Style Search On Lightning Speed For Fashion Attributes And Colours

While fashion product searches typically take 1.3 – 7 seconds, Mixi not only pins it within 1 second with more than 90% accuracy rate (industry rate less than 50%), but also brings along personalization because of AI machine learning capacity. Mixi’s automatic tagging is enabled by its unprecedented power to recognize over 2,300 colours and over 230 fashion attributes. Instant and relevant style searches are made possible by an intelligent fine-grained fashion attribute and colour recognition system.

Web-based AiDA is currently offering to users in Europe and Asia Pacific, and is a prerequisite in new curriculum of bachelor’s degree programme at the School of Fashion and Textiles of The Hong Kong Polytechnic University.

Hashtag: #Code-Create

The issuer is solely responsible for the content of this announcement.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Bird Global, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm – BRDS

New York, New York – Newsfile Corp. – December 20, 2022 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Bird Global, Inc. (NYSE: BRDS) between May 14, 2021 and November 14, 2022, both dates inclusive (the “Class Period”), of the important January 17, 2023 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased Bird securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Bird class action, go to https://rosenlegal.com/submit-form/?case_id=9805 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Bird was improperly recording Sharing Revenue for certain trips by its customers where collection was not probable; (2) as such, Bird overstated its Sharing Revenue for the relevant quarters and fiscal year during the Class Period; (3) Bird failed to disclose that its internal controls were not effective as they relate to calculating Sharing Revenue recognition; (4) as a result, Bird would need to restate its previously disclosed Sharing Revenue; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Bird class action, go to https://rosenlegal.com/submit-form/?case_id=9805 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

The issuer is solely responsible for the content of this announcement.

ROSEN, A RESPECTED AND LEADING FIRM, Encourages Core Scientific, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORZ

New York, New York – Newsfile Corp. – December 20, 2022 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Core Scientific, Inc. (NASDAQ: CORZ) between January 3, 2022 and October 26, 2022, both dates inclusive (the “Class Period”), of the important January 13, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Core Scientific securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Core Scientific class action, go to https://rosenlegal.com/submit-form/?case_id=3932 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 13, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) due in part to the expiration of a favorable pricing agreement, Core Scientific was experiencing increasing power costs; (2) Core Scientific’s largest customer, Gryphon, lacked the financial resources to purchase the necessary miner rigs for Core Scientific to host; (3) Core Scientific was not providing hosting services to Celsius Network LLC and related entities (“Celsius”) as required by their contract; (4) Core Scientific had implemented an improper surcharge to pass through power costs to Celsius; (5) as a result of the foregoing alleged breaches of contract, Core Scientific was reasonably likely to incur liability to defend itself against Celsius; (6) as a result of the foregoing, Core Scientific’s profitability would be adversely impacted; (7) as a result, there was likely substantial doubt as to Core Scientific’s ability to continue as a going concern; and (8) as a result, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Core Scientific class action, go to https://rosenlegal.com/submit-form/?case_id=3932 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

The issuer is solely responsible for the content of this announcement.

Apple to Produce MacBook Products in Vietnam from Next Year

Apple to produce MacBook in Vietnam.

Apple’s MacBooks will be manufactured in Vietnam next year, the latest of several Apple products to be shifted to the country.